Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Fumitoshi SatohSetsuko Iijima

Abstract

Mineralocorticoid receptor (MR) blockers are very beneficial for patients with hypertension and primary aldosteronism (PA). We investigated the efficacy and safety of a newly available nonsteroidal MR blocker, esaxerenone, in Japanese patients with hypertension and PA. A multicenter, open-label study was conducted in Japan between October 2016 and July 2017. Patients with hypertension and PA received 12 weeks of treatment with esaxerenone, initiated at 2.5 mg/day and escalated to 5 mg/day during week 2 or 4 of treatment, based on individual response. The only other permitted antihypertensive therapies were stable dosages of a Ca2+ channel blocker or α-blocker. The primary efficacy outcome was a change in sitting systolic and diastolic blood pressure (SBP/DBP) from baseline to the end of treatment. Forty-four patients were included; dose escalation to 5 mg/day was implemented for 41 of these patients. Significant decreases in SBP and DBP were observed (point estimates [95% confidence interval] -17.7 [-20.6, -14.7] and -9.5 [-11.7, -7.3] mmHg, respectively; both p < 0.0001 at the end of treatment). Significant BP reductions were evident from week 2 and continued through to week 8; BP remained stable until week 12. The antihyperte...Continue Reading

References

Dec 7, 2002·Hypertension·David A CalhounPaula Weissmann
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Oct 24, 2003·American Journal of Hypertension·Mari Konishi NishizakaDavid A Calhoun
Apr 1, 2005·Journal of the American Society of Nephrology : JASN·Jean RibsteinAlbert Mimran
Nov 18, 2005·The Journal of Clinical Endocrinology and Metabolism·Francesco FalloPaolo Mulatero
Dec 13, 2006·Journal of the American College of Cardiology·Gian Paolo RossiUNKNOWN PAPY Study Investigators
Feb 21, 2007·Hypertension·Neil ChapmanUNKNOWN Anglo-Scandinavian Cardiac Outcomes Trial Investigators
Mar 4, 2008·Expert Opinion on Pharmacotherapy·Asterios KaragiannisDimitri P Mikhailidis
Feb 5, 2009·The Journal of Clinical Endocrinology and Metabolism·E Born-FrontsbergUNKNOWN Participants of the German Conn's Registry
Aug 11, 2011·Endocrine Journal·Tetsuo NishikawaUNKNOWN Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society
Sep 27, 2012·Journal of Hypertension·GianLuca ColussiLeonardo A Sechi
Nov 23, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsuhisa Sato
Sep 24, 2013·The Journal of Clinical Endocrinology and Metabolism·Paolo MulateroFranco Veglio
Sep 26, 2015·International Journal of Cardiology·Mitja LainscakCarlo Gaudio
Nov 27, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shigehiro KarashimaYoshiyu Takeda
Mar 5, 2016·The Journal of Clinical Endocrinology and Metabolism·John W FunderWilliam F Young
Mar 24, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Anand VaidyaUNKNOWN AACE Adrenal Scientific Committee
Jun 4, 2017·The Lancet. Diabetes & Endocrinology·Tracy A WilliamsUNKNOWN Primary Aldosteronism Surgery Outcome (PASO) investigators
Nov 2, 2017·The Journal of Clinical Endocrinology and Metabolism·Hironobu UmakoshiUNKNOWN JPAS Study Group
Apr 6, 2019·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Minoru SatohHirotaka Shibata
Jun 27, 2019·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroshi ItohSatoshi Nishioka
Jul 19, 2019·European Journal of Endocrinology·Akiyuki KawashimaMitsuhide Naruse

❮ Previous
Next ❯

Citations

Oct 16, 2021·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaki MogiKazuomi Kario

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02885662

Software Mentioned

SAS

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.